References
[1] Faguet GB. A brief history of cancer: age-old milestones underlying our current knowledge database. Int J Cancer. 2015;136(9):2022-36.
[2] Toledo-Pereyra LH. Medical renaissance. J Invest Surg. 2015;28(3):127-30.
[3] Barclay JA. The Billroth I gastrectomy. Can Med Assoc J. 1952;67(1):41-2.
[4] Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264-79.
[5] Li Y, et al. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(6):553-64.
[6] Miehlke S, Kirsch C, Agha-Amiri K, et al. The Helicobacter pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany. Int J Cancer. 2000;87(3):322-7.
[7] Zeng W, et al. The clinicopathological significance of CDH1 in gastric cancer: a meta-analysis and systematic review. Drug Des Devel Ther. 2015;9:2149-57.
[8] Leung WK, Sung JJ. Review article: intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther. 2002;16(7):1209-16.
[9] Sugano K, Moss SF, Kuipers EJ. Gastric intestinal metaplasia: real culprit or innocent bystander as a precancerous condition for gastric cancer? Gastroenterology. 2023;165(6):1352-66.e1.
[10] Cover TL, Lacy DB, Ohi MD. The Helicobacter pylori Cag Type IV Secretion System. Trends Microbiol. 2020;28(8):682-95.
[11] Kinoshita H, Hayakawa Y, Koike K. Metaplasia in the stomach-precursor of gastric cancer? Int J Mol Sci. 2017;18(10).
[12] Tong Q, et al. Gastric intestinal metaplasia: progress and remaining challenges. J Gastroenterol. 2024;59(4):285-301.
[13] Codolo G, et al. HP-NAP of Helicobacter pylori: the power of the immunomodulation. Front Immunol. 2022;13:944139.
[14] Nemati M, Larussa T, Khorramdelazad H, et al. Toll-like receptor 2: an important immunomodulatory molecule during Helicobacter pylori infection. Life Sci. 2017;178:17-29.
[15] Yu X, et al. Gut microbiota modulate CD8+ T cell immunity in gastric cancer through Butyrate/GPR109A/HOPX. Gut Microbes. 2024;16(1):2307542.
[16] Venerito M, Vasapolli R, Rokkas T, et al. Helicobacter pylori and gastrointestinal malignancies. Helicobacter. 2015;20 Suppl 1:36-9.
[17] Barros R, Freund JN, David L, et al. Gastric intestinal metaplasia revisited: function and regulation of CDX2. Trends Mol Med. 2012;18(9):555-63.
[18] Sun C, et al. Spatially resolved multi-omics highlights cell-specific metabolic remodeling and interactions in gastric cancer. Nat Commun. 2023;14(1):2692.
[19] Tsubosaka A, et al. Stomach encyclopedia: combined single-cell and spatial transcriptomics reveal cell diversity and homeostatic regulation of human stomach. Cell Rep. 2023;42(10):113236.
[20] Sugimoto M, et al. Using texture and colour enhancement imaging to evaluate gastrointestinal diseases in clinical practice: a review. Ann Med. 2022;54(1):3315-32.
[21] Zhang H, Deng T, Liu R, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020;19(1):43.
[22] Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in meta-static gastric cancer. Nat Med. 2018;24(9):1449-58.
[23] Nakamura Y, Kawazoe A, Lordick F, et al. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol. 2021;18(8):473-87.